[Intermittent androgen deprivation in advanced prostate cancer: a review].
At present androgen ablation therapy is the therapy of choice for the treatment of metastatic prostate cancer. However, in more than 50 % of the patients the disease will ultimately progress within 2 years.On the basis of the postulation from Bruchovsky et al. that intermittent androgen deprivation maintains the apoptotic potential, this may lead to a delay in tumour progression. By periodically changing phases from on to off the treatment quality of life for the patient may be improved. Most recent clinical data of phase II and III studies imply that IAB is equal effective as CAB. Although data about quality of life and overall survival are still limited, results seem to be comparable. In order to decide which patient groups are most likely to benefit from IAB, final phase III results need to be available.
Urologische Klinik, AKH Viersen, Viersen. Wolff@akh-viersen.de
J M
JM
Wolff
D000726:Androgen Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D000818:Animals; D014408:Biomarkers, Tumor / Q000097:blood; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D004195:Disease Models, Animal; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D011788:Quality of Life; D016019:Survival Analysis
D000726:Androgen Antagonists; D014408:Biomarkers, Tumor; D017430:Prostate-Specific Antigen